Dihydropyridine Derivatives Modulate Heat Shock Responses and have a Neuroprotective Effect in a Transgenic Mouse Model of Alzheimer's Disease.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model study (APPxPS1 transgenic mice).
PubMed 27163800 · doi:10.3233/JAD-150860
What was done
Researchers evaluated the neuroprotective effects of LA1011, a 1,4-dihydropyridine derivative and heat shock protein (Hsp) co-inducer, in wild-type and APPxPS1 double mutant transgenic mouse models of Alzheimer's disease. The compound was administered for 6 months, and outcomes included spatial learning and memory, neuronal counts, dendritic spine density, tau pathology, and amyloid-beta plaque burden.
What was found
The abstract reports no numerical data, confidence intervals, or statistical test values. Qualitatively, 6 months of LA1011 treatment improved spatial learning and memory in wild-type mice, reduced neurodegeneration in APPxPS1 mice, preserved neuron counts, increased dendritic spine density, and decreased both tau pathology and amyloid plaque formation.
Why it matters
This study demonstrates that targeting protein homeostasis through pharmacological co-induction of heat shock proteins can mitigate hallmark Alzheimer's pathology in a mouse model.
Limits
The study was conducted entirely in transgenic mice, which do not fully replicate human Alzheimer's pathology or clinical outcomes. The abstract omits sample sizes, dosage, delivery route, and all quantitative measurements.
Cited by
- supports In animal models, heat shock proteins protect against the aggregation of amyloid-beta 42 associated with Alzheimer's disease.